SLC5A2 and type 2 diabetes mellitus: Like for SGLT2 inhibitors, data from clinical trials conducted in patients with T2DM have shown that treatment with GLP1 receptor agonists reduced the risk of cardiovascular events and slowed the development of albuminuria in diabetic patients, demonstrating a direct cardio- and renoprotective action independent of their effect on glycemic control [1,126].